Prof Johnny Mahlangu

Johnny Mahlangu is an internationally recognized hematologist and clinician-scientist specializing in bleeding disorders, particularly hemophilia. Based in South Africa and affiliated with leading academic and clinical institutions in Johannesburg, he has played a central role in advancing comprehensive hemophilia care across Africa and globally. His leadership within international thrombosis and hemostasis societies has positioned him as a key voice in shaping clinical standards and access initiatives.

His recent publications highlight a strong focus on gene therapy for hemophilia A, including adeno-associated virus platforms, lentiviral strategies, and the clinical management of therapy-related complications such as transaminitis. He contributes to consensus guidance on standardization, safety monitoring, and optimization of factor expression, reflecting deep expertise in translational research and regulatory science.

Additional work spans recombinant factor innovations, bypassing agents, emicizumab prophylaxis, and surgical management in severe hemophilia. Through clinical trials, real-world studies, and mechanistic analyses, his research advances therapeutic efficacy, inhibitor management, and equitable access to novel treatments, particularly within resource-constrained settings.